All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type ECOG ⩾ 1 ECOG 0 ECOG 1 Gender, female Gender, male Hemoglobin concentration < 10g/dl hemoglobin concentration > 10g/dl metastasis (liver ) metastasis (lymph node ) metastasis (visceral) PD-L1 < 1% PD-L1 < 10% PD-L1 < 5% PD-L1 > 1% PD-L1 > 10% PD-L1 > 5% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) PDL1 < 25% PDL1 >25% smoker (current or former) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
urothelial cancer (UC) - bladder cancer (BC), anti-PD-(L)1 vs. chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results DANUBE (D vs C - all population), 2020 0.99 [0.83; 1.18]
DANUBE (D vs C - PDL1>25%), 2020 0.89 [0.71; 1.11]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.83 [0.69; 1.00]
IMvigor-130 (At-arm B vs Ch-armC), 2020 1.02 [0.83; 1.25]
IMvigor-211 (all population), 2018 0.85 [0.73; 0.99]
IMvigor-211 (PDL1>1%), 2018 0.87 [0.72; 1.06]
IMvigor-211 (PDL1>5%), 2018 0.87 [0.63; 1.21]
KEYNOTE-045 (all population), 2017 0.73 [0.59; 0.91]
KEYNOTE-045 (PDL1 CPS >10%), 2017 0.57 [0.37; 0.88]
KEYNOTE-361 (P vs C), 2021 0.92 [0.77; 1.10]
KEYNOTE-361 (PC vs C), 2021 0.86 [0.72; 1.02]
0.87 [0.82 ; 0.93 ] DANUBE (D vs C - all population), 2020, DANUBE (D vs C - PDL1>25%), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-045 (PDL1 CPS >10%), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 11 13% 6,575 moderate low deaths (OS) (extension)detailed results IMvigor-211 (all population), 2018 0.82 [0.71; 0.94]
IMvigor-211 (PDL1>5%), 2018 0.87 [0.64; 1.18]
KEYNOTE-045 (all population), 2017 0.70 [0.57; 0.85]
0.79 [0.71 ; 0.88 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 3 3% 1,707 moderate not evaluable PFS (extension)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.79; 1.16]
0.96 [0.79 ; 1.16 ] KEYNOTE-045 (all population), 2017 1 0% 542 NA not evaluable progression or deaths (PFS)detailed results DANUBE (D vs C - all population), 2020 0.77 [0.54; 1.09]
DANUBE (D vs C - PDL1>25%), 2020 1.24 [0.74; 2.08]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.82 [0.70; 0.96]
IMvigor-211 (all population), 2018 0.89 [0.60; 1.32]
IMvigor-211 (PDL1>1%), 2018 0.86 [0.53; 1.39]
IMvigor-211 (PDL1>5%), 2018 1.01 [0.76; 1.35]
KEYNOTE-045 (all population), 2017 0.98 [0.81; 1.19]
KEYNOTE-045 (PDL1 CPS >10%), 2017 0.89 [0.61; 1.29]
KEYNOTE-361 (P vs C), 2021 1.35 [1.12; 1.63]
KEYNOTE-361 (PC vs C), 2021 0.78 [0.65; 0.93]
0.94 [0.82 ; 1.08 ] DANUBE (D vs C - all population), 2020, DANUBE (D vs C - PDL1>25%), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-045 (PDL1 CPS >10%), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 10 64% 5,815 moderate low CRR detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.96 [1.21; 3.17]
1.96 [1.21 ; 3.17 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 851 NA not evaluable DORdetailed results DANUBE (D vs C - all population), 2020 0.35 [0.20; 0.62]
DANUBE (D vs C - PDL1>25%), 2020 0.27 [0.13; 0.57]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.70 [0.46; 1.08]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.21 [0.12; 0.37]
IMvigor-211 (all population), 2018 0.16 [0.07; 0.35]
IMvigor-211 (PDL1>1%), 2018 0.20 [0.08; 0.50]
IMvigor-211 (PDL1>5%), 2018 0.16 [0.04; 0.55]
KEYNOTE-045 (all population), 2017 4.66 [1.83; 11.87]
0.37 [0.19 ; 0.71 ] DANUBE (D vs C - all population), 2020, DANUBE (D vs C - PDL1>25%), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 8 86% 1,410 moderate not evaluable objective responses (ORR)detailed results DANUBE (D vs C - all population), 2020 0.36 [0.26; 0.49]
DANUBE (D vs C - PDL1>25%), 2020 0.41 [0.27; 0.62]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.15 [0.88; 1.51]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.38 [0.28; 0.53]
IMvigor-211 (all population), 2018 0.99 [0.68; 1.45]
IMvigor-211 (PDL1>1%), 2018 0.95 [0.61; 1.49]
IMvigor-211 (PDL1>5%), 2018 1.07 [0.58; 2.00]
KEYNOTE-045 (all population), 2017 2.08 [1.29; 3.34]
KEYNOTE-045 (PDL1 CPS >10%), 2017 3.86 [1.43; 10.46]
KEYNOTE-361 (P vs C), 2021 0.53 [0.39; 0.74]
KEYNOTE-361 (PC vs C), 2021 1.48 [1.10; 2.00]
0.87 [0.59 ; 1.29 ] DANUBE (D vs C - all population), 2020, DANUBE (D vs C - PDL1>25%), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-045 (PDL1 CPS >10%), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 11 91% 6,575 moderate low objective responses (ORR) (extension)detailed results KEYNOTE-045 (all population), 2017 2.16 [1.34; 3.48]
KEYNOTE-045 (PDL1 CPS >10%), 2017 3.56 [1.30; 9.71]
2.37 [1.54 ; 3.65 ] KEYNOTE-045 (all population), 2017, KEYNOTE-045 (PDL1 CPS >10%), 2017 2 0% 706 moderate not evaluable AE (any grade)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.34 [0.43; 12.83]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.14 [0.05; 0.40]
IMvigor-211 (all population), 2018 0.38 [0.17; 0.88]
IMvigor-211 (PDL1>5%), 2018 0.67 [0.11; 4.10]
KEYNOTE-045 (all population), 2017 0.28 [0.10; 0.75]
0.39 [0.18 ; 0.84 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 5 53% 3,236 moderate not evaluable AE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.37 [0.27; 0.52]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.92 [0.63; 1.34]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.12 [0.08; 0.17]
IMvigor-211 (all population), 2018 0.80 [0.62; 1.04]
IMvigor-211 (PDL1>5%), 2018 1.38 [0.81; 2.33]
KEYNOTE-045 (all population), 2017 0.61 [0.43; 0.86]
0.55 [0.29 ; 1.05 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 6 95% 3,894 moderate not evaluable AE (grade 3-5)detailed results KEYNOTE-361 (P vs C), 2021 0.38 [0.26; 0.54]
KEYNOTE-361 (PC vs C), 2021 1.53 [1.01; 2.33]
0.76 [0.19 ; 3.00 ] KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 2 96% 1,335 moderate not evaluable AE leading to death (grade 5)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.27 [0.70; 2.27]
IMvigor-130 (At-arm B vs Ch-armC), 2020 1.59 [0.88; 2.87]
IMvigor-211 (all population), 2018 0.91 [0.46; 1.79]
IMvigor-211 (PDL1>5%), 2018 0.73 [0.16; 3.34]
KEYNOTE-045 (all population), 2017 1.59 [0.65; 3.89]
KEYNOTE-361 (P vs C), 2021 3.49 [1.61; 7.56]
KEYNOTE-361 (PC vs C), 2021 3.74 [1.75; 7.95]
1.69 [1.10 ; 2.58 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 7 54% 4,571 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results DANUBE (D vs C - all population), 2020 0.66 [0.43; 1.03]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.05 [0.79; 1.40]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.13 [0.08; 0.21]
IMvigor-211 (all population), 2018 0.37 [0.24; 0.57]
IMvigor-211 (PDL1>5%), 2018 0.44 [0.20; 0.99]
KEYNOTE-045 (all population), 2017 0.63 [0.35; 1.11]
KEYNOTE-361 (P vs C), 2021 0.85 [0.56; 1.29]
KEYNOTE-361 (PC vs C), 2021 2.02 [1.42; 2.89]
0.61 [0.34 ; 1.08 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 8 93% 5,248 moderate not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.85 [0.44; 1.65]
0.85 [0.44 ; 1.65 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable SAE (any grade)detailed results DANUBE (D vs C - all population), 2020 1.01 [0.74; 1.39]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.11 [0.85; 1.46]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.78 [0.59; 1.05]
IMvigor-211 (all population), 2018 0.92 [0.70; 1.19]
IMvigor-211 (PDL1>5%), 2018 1.79 [1.05; 3.05]
1.02 [0.83 ; 1.25 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 5 52% 3,373 moderate not evaluable STRAE (any grade)detailed results DANUBE (D vs C - all population), 2020 0.50 [0.31; 0.81]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.33 [0.99; 1.80]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.41 [0.28; 0.60]
IMvigor-211 (all population), 2018 0.56 [0.40; 0.78]
IMvigor-211 (PDL1>5%), 2018 0.92 [0.48; 1.80]
KEYNOTE-361 (P vs C), 2021 0.39 [0.26; 0.59]
KEYNOTE-361 (PC vs C), 2021 1.16 [0.83; 1.61]
0.68 [0.45 ; 1.02 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 7 87% 4,708 moderate not evaluable TRAE (any grade)detailed results DANUBE (D vs C - all population), 2020 0.13 [0.09; 0.21]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.04 [0.53; 2.03]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.07 [0.04; 0.11]
IMvigor-211 (all population), 2018 0.28 [0.19; 0.40]
IMvigor-211 (PDL1>5%), 2018 0.38 [0.19; 0.79]
KEYNOTE-045 (all population), 2017 0.17 [0.10; 0.28]
KEYNOTE-361 (P vs C), 2021 0.08 [0.04; 0.14]
0.20 [0.11 ; 0.36 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 7 90% 4,538 moderate not evaluable TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.10 [0.07; 0.15]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.02 [0.72; 1.43]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.04 [0.03; 0.06]
IMvigor-211 (all population), 2018 0.33 [0.25; 0.45]
IMvigor-211 (PDL1>5%), 2018 0.55 [0.31; 0.99]
KEYNOTE-045 (all population), 2017 0.19 [0.12; 0.28]
KEYNOTE-361 (P vs C), 2021 0.08 [0.05; 0.12]
KEYNOTE-361 (PC vs C), 2021 1.19 [0.85; 1.67]
0.25 [0.11 ; 0.59 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 8 98% 5,229 moderate not evaluable TRAE leading to death (grade 5)detailed results DANUBE (D vs C - all population), 2020 1.82 [0.16; 20.16]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.96 [0.60; 6.40]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.82 [0.18; 3.71]
IMvigor-211 (all population), 2018 0.42 [0.13; 1.39]
IMvigor-211 (PDL1>5%), 2018 0.98 [0.14; 7.10]
KEYNOTE-045 (all population), 2017 0.96 [0.24; 3.87]
KEYNOTE-361 (P vs C), 2021 1.13 [0.16; 8.10]
KEYNOTE-361 (PC vs C), 2021 0.98 [0.14; 7.00]
0.97 [0.56 ; 1.67 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 8 0% 5,229 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results DANUBE (D vs C - all population), 2020 0.46 [0.26; 0.79]
IMvigor-211 (all population), 2018 0.22 [0.12; 0.38]
IMvigor-211 (PDL1>5%), 2018 0.37 [0.15; 0.92]
KEYNOTE-045 (all population), 2017 0.48 [0.25; 0.93]
0.36 [0.24 ; 0.53 ] DANUBE (D vs C - all population), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 4 34% 2,307 moderate not evaluable Abdominal pain TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12]
3.64 [0.16 ; 81.12 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.45 [0.02; 13.55]
0.45 [0.02 ; 13.55 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
KEYNOTE-045 (all population), 2017 1.92 [0.06; 57.51]
KEYNOTE-361 (P vs C), 2021 1.13 [0.02; 57.26]
KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
1.47 [0.24 ; 9.04 ] DANUBE (D vs C - all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 4 0% 2,514 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35]
KEYNOTE-045 (all population), 2017 0.24 [0.01; 5.31]
0.60 [0.06 ; 5.94 ] DANUBE (D vs C - all population), 2020, KEYNOTE-045 (all population), 2017 2 0% 1,179 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.05 [0.02; 0.13]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.11 [0.67; 1.84]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.07 [0.02; 0.30]
IMvigor-211 (all population), 2018 0.40 [0.18; 0.89]
IMvigor-211 (PDL1>5%), 2018 0.98 [0.19; 4.97]
KEYNOTE-045 (all population), 2017 0.07 [0.02; 0.31]
KEYNOTE-361 (P vs C), 2021 0.02 [0.01; 0.07]
KEYNOTE-361 (PC vs C), 2021 0.87 [0.63; 1.20]
0.21 [0.08 ; 0.55 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 8 92% 5,229 moderate serious Arthralgia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Arthritis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Asthenia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.25 [0.05; 1.24]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.00 [0.82; 4.92]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.63 [0.18; 2.15]
IMvigor-211 (all population), 2018 0.42 [0.18; 0.97]
IMvigor-211 (PDL1>5%), 2018 0.49 [0.04; 5.45]
KEYNOTE-045 (all population), 2017 0.13 [0.02; 1.09]
KEYNOTE-361 (P vs C), 2021 0.12 [0.02; 0.98]
KEYNOTE-361 (PC vs C), 2021 0.98 [0.38; 2.50]
0.55 [0.29 ; 1.06 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 8 50% 5,229 moderate not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.45 [0.02; 13.55]
0.45 [0.02 ; 13.55 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Colitis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
KEYNOTE-045 (all population), 2017 5.81 [0.29; 116.49]
KEYNOTE-361 (P vs C), 2021 4.58 [0.51; 41.18]
KEYNOTE-361 (PC vs C), 2021 1.97 [0.18; 21.78]
3.06 [0.80 ; 11.68 ] DANUBE (D vs C - all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 4 0% 2,514 moderate not evaluable Constipation TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
IMvigor-211 (all population), 2018 0.02 [0.00; 0.38]
IMvigor-211 (PDL1>5%), 2018 0.12 [0.01; 2.28]
KEYNOTE-045 (all population), 2017 0.06 [0.00; 1.02]
KEYNOTE-361 (P vs C), 2021 1.13 [0.16; 8.10]
KEYNOTE-361 (PC vs C), 2021 0.24 [0.01; 5.43]
0.20 [0.05 ; 0.76 ] DANUBE (D vs C - all population), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 6 25% 3,642 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.68 [0.15; 3.05]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.59 [0.27; 25.03]
IMvigor-130 (At-arm B vs Ch-armC), 2020 2.21 [0.20; 24.48]
KEYNOTE-045 (all population), 2017 0.16 [0.01; 3.17]
KEYNOTE-361 (P vs C), 2021 0.38 [0.04; 3.63]
KEYNOTE-361 (PC vs C), 2021 0.32 [0.03; 3.14]
0.70 [0.29 ; 1.68 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 6 0% 4,101 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
KEYNOTE-361 (P vs C), 2021 2.27 [0.08; 67.88]
KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
1.68 [0.22 ; 13.01 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 0% 1,993 moderate not evaluable Diarrhoea TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.36 [0.07; 1.86]
KEYNOTE-045 (all population), 2017 1.44 [0.24; 8.71]
KEYNOTE-361 (P vs C), 2021 0.90 [0.24; 3.40]
KEYNOTE-361 (PC vs C), 2021 1.38 [0.43; 4.39]
0.96 [0.47 ; 1.95 ] DANUBE (D vs C - all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 4 0% 2,514 moderate not evaluable Dyspnoea TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12]
3.64 [0.16 ; 81.12 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Fatigue TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.11 [0.01; 0.89]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.61 [0.70; 9.73]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.73 [0.12; 4.41]
IMvigor-211 (all population), 2018 0.37 [0.15; 0.88]
IMvigor-211 (PDL1>5%), 2018 2.00 [0.36; 11.15]
KEYNOTE-045 (all population), 2017 0.25 [0.07; 0.92]
KEYNOTE-361 (P vs C), 2021 0.50 [0.15; 1.63]
KEYNOTE-361 (PC vs C), 2021 0.87 [0.33; 2.28]
0.62 [0.33 ; 1.16 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 8 46% 5,229 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.15 [0.01; 3.01]
IMvigor-211 (all population), 2018 0.04 [0.00; 0.27]
IMvigor-211 (PDL1>5%), 2018 0.09 [0.01; 1.75]
0.06 [0.02 ; 0.27 ] DANUBE (D vs C - all population), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 3 0% 1,786 moderate not evaluable Gastritis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35]
1.82 [0.06 ; 54.35 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 5.48 [0.27; 109.88]
KEYNOTE-361 (P vs C), 2021 2.27 [0.08; 67.88]
KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
3.07 [0.47 ; 19.99 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 0% 1,993 moderate not evaluable Hypersensitivity TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.45 [0.02; 13.55]
0.45 [0.02 ; 13.55 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
KEYNOTE-361 (P vs C), 2021 1.13 [0.02; 57.26]
KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
1.23 [0.19 ; 8.07 ] DANUBE (D vs C - all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 4 0% 2,514 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
KEYNOTE-361 (P vs C), 2021 2.27 [0.08; 67.88]
KEYNOTE-361 (PC vs C), 2021 5.92 [0.30; 118.67]
2.72 [0.39 ; 19.09 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 0% 1,993 moderate not evaluable Hypothyroidism TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
KEYNOTE-361 (P vs C), 2021 2.27 [0.08; 67.88]
KEYNOTE-361 (PC vs C), 2021 3.94 [0.18; 87.61]
2.25 [0.31 ; 16.26 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 0% 1,993 moderate not evaluable Increase AST TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.13; 6.48]
0.91 [0.13 ; 6.48 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 2.74 [0.28; 26.45]
2.74 [0.28 ; 26.45 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 6.46 [0.79; 52.82]
6.46 [0.79 ; 52.82 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
0.93 [0.06 ; 14.94 ] DANUBE (D vs C - all population), 2020, KEYNOTE-045 (all population), 2017 2 0% 1,179 moderate not evaluable Leucopenia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.04 [0.00; 0.62]
KEYNOTE-361 (P vs C), 2021 0.01 [0.00; 0.13]
KEYNOTE-361 (PC vs C), 2021 0.68 [0.38; 1.24]
0.07 [0.00 ; 1.54 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 84% 1,993 moderate not evaluable Myocarditis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12]
KEYNOTE-361 (P vs C), 2021 1.13 [0.02; 57.26]
KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
2.19 [0.30 ; 15.87 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 0% 1,993 moderate not evaluable Myositis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35]
KEYNOTE-045 (all population), 2017 0.48 [0.02; 14.32]
KEYNOTE-361 (P vs C), 2021 1.13 [0.02; 57.26]
KEYNOTE-361 (PC vs C), 2021 0.98 [0.02; 49.53]
0.98 [0.16 ; 6.04 ] DANUBE (D vs C - all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 4 0% 2,514 moderate not evaluable Nausea TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.06 [0.00; 0.97]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.73 [0.31; 9.49]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.27 [0.01; 6.11]
KEYNOTE-045 (all population), 2017 0.24 [0.03; 2.13]
KEYNOTE-361 (P vs C), 2021 0.28 [0.06; 1.32]
KEYNOTE-361 (PC vs C), 2021 0.85 [0.31; 2.38]
0.50 [0.22 ; 1.14 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 6 22% 4,101 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12]
KEYNOTE-045 (all population), 2017 3.86 [0.17; 85.92]
KEYNOTE-361 (P vs C), 2021 2.27 [0.08; 67.88]
KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
2.89 [0.57 ; 14.59 ] DANUBE (D vs C - all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 4 0% 2,514 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.01 [0.00; 0.09]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.01 [1.12; 3.62]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.03 [0.00; 0.52]
IMvigor-211 (all population), 2018 0.04 [0.01; 0.15]
IMvigor-211 (PDL1>5%), 2018 0.20 [0.04; 0.97]
KEYNOTE-045 (all population), 2017 0.01 [0.00; 0.19]
KEYNOTE-361 (P vs C), 2021 0.00 [0.00; 0.07]
KEYNOTE-361 (PC vs C), 2021 0.94 [0.67; 1.32]
0.09 [0.03 ; 0.34 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 8 90% 5,229 moderate serious Pancreatitis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
KEYNOTE-361 (P vs C), 2021 4.55 [0.20; 101.37]
KEYNOTE-361 (PC vs C), 2021 3.94 [0.18; 87.61]
2.93 [0.43 ; 19.90 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 0% 1,993 moderate not evaluable Pancytopenia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.11 [0.01; 2.13]
0.11 [0.01 ; 2.13 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.12 [0.01; 0.95]
IMvigor-211 (PDL1>5%), 2018 0.32 [0.03; 3.14]
KEYNOTE-045 (all population), 2017 0.24 [0.01; 5.31]
0.20 [0.05 ; 0.78 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 3 0% 1,649 moderate not evaluable Pneumonitis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12]
KEYNOTE-045 (all population), 2017 9.75 [0.53; 179.40]
KEYNOTE-361 (P vs C), 2021 4.58 [0.51; 41.18]
KEYNOTE-361 (PC vs C), 2021 2.96 [0.31; 28.57]
4.44 [1.25 ; 15.74 ] DANUBE (D vs C - all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 4 0% 2,514 moderate not evaluable Pruritic rash TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Pruritus TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.72 [0.06; 51.51]
IMvigor-130 (At-arm B vs Ch-armC), 2020 1.10 [0.02; 55.68]
KEYNOTE-045 (all population), 2017 0.48 [0.02; 14.32]
KEYNOTE-361 (P vs C), 2021 1.13 [0.02; 57.26]
KEYNOTE-361 (PC vs C), 2021 5.92 [0.30; 118.67]
1.64 [0.40 ; 6.73 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 6 0% 4,101 moderate not evaluable Pyrexia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.23 [0.01; 5.02]
0.23 [0.01 ; 5.02 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Rash TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.86 [0.02; 43.49]
IMvigor-130 (At-arm B vs Ch-armC), 2020 4.43 [0.20; 98.49]
KEYNOTE-361 (P vs C), 2021 0.57 [0.02; 16.92]
KEYNOTE-361 (PC vs C), 2021 3.95 [0.44; 35.56]
2.48 [0.66 ; 9.36 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 5 0% 3,580 moderate not evaluable Sarcoidosis TRAE (grade 3-4)detailed results KEYNOTE-361 (P vs C), 2021 1.13 [0.02; 57.26]
KEYNOTE-361 (PC vs C), 2021 0.98 [0.02; 49.53]
1.05 [0.07 ; 16.88 ] KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 2 0% 1,335 moderate not evaluable Sepsis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.06; 14.56]
0.91 [0.06 ; 14.56 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.32 [0.03; 3.07]
KEYNOTE-361 (P vs C), 2021 1.13 [0.16; 8.10]
KEYNOTE-361 (PC vs C), 2021 3.99 [0.84; 18.92]
1.36 [0.32 ; 5.68 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 41% 1,856 moderate not evaluable Stevens-Johnson syndrome TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35]
1.82 [0.06 ; 54.35 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.02 [0.00; 0.29]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.11 [0.55; 2.26]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.08 [0.01; 0.58]
KEYNOTE-361 (P vs C), 2021 0.02 [0.00; 0.13]
KEYNOTE-361 (PC vs C), 2021 0.80 [0.52; 1.24]
0.20 [0.05 ; 0.71 ] DANUBE (D vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 5 85% 3,580 moderate serious Thyroiditis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
KEYNOTE-361 (P vs C), 2021 2.27 [0.08; 67.88]
KEYNOTE-361 (PC vs C), 2021 0.98 [0.02; 49.53]
1.24 [0.19 ; 8.17 ] DANUBE (D vs C - all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 4 0% 2,514 moderate not evaluable Vomiting TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.09 [0.00; 1.64]
KEYNOTE-361 (P vs C), 2021 0.14 [0.02; 1.12]
KEYNOTE-361 (PC vs C), 2021 1.11 [0.42; 2.90]
0.34 [0.06 ; 1.92 ] DANUBE (D vs C - all population), 2020, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 60% 1,993 moderate not evaluable Abdominal pain AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.40 [0.10; 1.58]
0.40 [0.10 ; 1.58 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Acute kidney injury AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 2.27 [0.58; 8.88]
2.27 [0.58 ; 8.88 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Alopecia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.16 [0.01; 3.17]
0.16 [0.01 ; 3.17 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Anaemia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.08 [0.82; 1.42]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.08 [0.05; 0.13]
KEYNOTE-045 (all population), 2017 0.65 [0.37; 1.16]
0.38 [0.08 ; 1.85 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-045 (all population), 2017 3 97% 2,108 moderate not evaluable Arthralgia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.16 [0.01; 3.17]
0.16 [0.01 ; 3.17 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Asthenia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.43 [0.81; 2.50]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.51 [0.24; 1.10]
KEYNOTE-045 (all population), 2017 0.14 [0.03; 0.63]
0.56 [0.18 ; 1.73 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-045 (all population), 2017 3 81% 2,108 moderate not evaluable Back pain AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.17; 21.35]
1.92 [0.17 ; 21.35 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Blood and lymphatic system disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.24 [0.15; 0.40]
0.24 [0.15 ; 0.40 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Blood creatinine increased AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.17; 21.35]
1.92 [0.17 ; 21.35 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Cardiac disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.72 [0.16; 3.23]
0.72 [0.16 ; 3.23 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Constipation AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.35 [0.09; 1.34]
0.35 [0.09 ; 1.34 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Cough AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.06; 57.51]
1.92 [0.06 ; 57.51 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Decreased appetite AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 3.28 [0.89; 12.06]
3.28 [0.89 ; 12.06 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Diarrhoea AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.24; 3.87]
0.96 [0.24 ; 3.87 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Dizziness AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.48 [0.02; 14.32]
0.48 [0.02 ; 14.32 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Dry skin AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
0.96 [0.02 ; 48.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Dysgeusia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
0.96 [0.02 ; 48.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Dyspnoea AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.61 [0.38; 6.80]
1.61 [0.38 ; 6.80 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Endocrine disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 5.81 [0.29; 116.49]
5.81 [0.29 ; 116.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Eye disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 3.86 [0.17; 85.92]
3.86 [0.17 ; 85.92 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Fatigue AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.66 [0.37; 1.17]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.22 [0.09; 0.54]
KEYNOTE-045 (all population), 2017 0.63 [0.28; 1.42]
0.48 [0.25 ; 0.91 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-045 (all population), 2017 3 53% 2,108 moderate not evaluable Febrile neutropenia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.76 [0.81; 3.80]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.05 [0.00; 0.92]
KEYNOTE-045 (all population), 2017 0.02 [0.00; 0.39]
0.16 [0.01 ; 3.75 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-045 (all population), 2017 3 85% 2,108 moderate not evaluable Gastrointestinal disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.42 [0.24; 0.75]
0.42 [0.24 ; 0.75 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable General disorders and administration site conditions AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.49 [0.28; 0.86]
0.49 [0.28 ; 0.86 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Headache AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.06; 57.51]
1.92 [0.06 ; 57.51 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Hypertension AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.22 [1.05; 4.68]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.54 [0.18; 1.61]
1.16 [0.29 ; 4.59 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020 2 77% 1,587 moderate not evaluable Hypothyroidism AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
0.96 [0.02 ; 48.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Increase AST AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 11.75 [0.65; 211.40]
11.75 [0.65 ; 211.40 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-04 03:31 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 11,288,153,157,290,155,154,289,188,189,239,158,252,253,76,238,236,237
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258